BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS

6. NVS
7. AZN
8. ORCL
9. AAPL
10. HOOD

Conference call and webcast to be held at 4:30 PM ET

July 29, 2026 4:05 PM EDT

E-mail

Get Alerts BSEM Hot Sheet

Price: $4.00 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

POMPANO BEACH, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET.

The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE.

Conference Call & Webcast Information:

Conference ID: 9695874
North America Toll-Free: (800) 715-9871
International Toll: +1 (646) 307-1963
Webcast Link: https://events.q4inc.com/attendee/199151484

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: [email protected]
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
[email protected]

Public Relations:
Jennifer Horton, Relevance
[email protected]